Status:

COMPLETED

Campath-1H Induction to Allow Discontinuation of Calcineurin Inhibitors After Renal Transplantation

Lead Sponsor:

University of Wisconsin, Madison

Conditions:

Primary Renal Transplant

Eligibility:

All Genders

18-75 years

Phase:

NA

Brief Summary

The purpose of this study is to determine whether Campath-1H induction therapy and the associated lymphocyte depletion will permit long-term, rejection free renal allograft function in the absence of ...

Eligibility Criteria

Inclusion

  • received a renal transplant, induction with Campath-1H, and at least 2 months of calcineurin inhibitor therapy, CellCept, and prednisone.

Exclusion

  • Recipients of HLA-identical living-donor renal transplants;
  • PRA value \>20% within 30 days of transplant;
  • GFR \<40ml/min;
  • multi-organ transplant;

Key Trial Info

Start Date :

May 1 2003

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 1 2009

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT00214201

Start Date

May 1 2003

End Date

May 1 2009

Last Update

October 3 2012

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of Wisconsin

Madison, Wisconsin, United States, 53792